New Diagnostic Tools Unveiled at EuroMedLab Exhibition
By LabMedica International staff writers Posted on 27 Jun 2017 |

Image: The Atellica1500 automated urinalysis system (Photo courtesy of Siemens Healthineers).
A major international manufacturer of automated diagnostic instruments and point-of-care diagnostic products has changed its name, a change that was highlighted at the IFCC EuroMedLab Athens June 12-14, 2017, exhibition.
Siemens Healthineers (Erlangen, Germany), which is the separately managed healthcare business of Siemens AG (Munich, Germany) presented its latest Atellica Portfolio offerings at the Athens exhibition.
The Portfolio included: Atellica Solution (flexible, scalable, automation-ready immunoassay, and clinical chemistry analyzers), Atellica 1500 Automated Urinalysis System (fully digital, automated urinalysis system), Atellica NEPH 630 System (mid-volume, dedicated nephelometric system that simplifies specialty protein testing), Atellica COAG 360 System (fully automated high-volume coagulation system that unifies five testing methodologies), Atellica MDX 160 System (flexible, automated molecular system with maximum productivity for multiple sample types), and Atellica PM 1.0 Software (process management software to optimize lab operations through data analytics and visualization).
In addition, the Athens presentation featured the RAPIDComm Data Management System, which enables centrally managed point-of-care testing programs through a single customizable interface.
“The 2017 product display from Siemens Healthineers represents our focus on engineering success and pioneering healthcare,” said Franz Walt, president of laboratory diagnostics at Siemens Healthineers. “The Atellica portfolio epitomizes engineering excellence - with revolutionary innovations designed to give lab professionals control and simplicity so they can spend less time on operations and more time on driving better outcomes.”
“The informatics solutions from Siemens Healthineers are designed to address connectivity challenges to help position point-of-care testing programs for success,” said Peter Koerte, president of point-of-care diagnostics at Siemens Healthineers. “Through open connectivity to more than 150 devices from all leading point-of-care vendors, we deliver secure - yet flexible - connectivity options that increase both choice and performance for greater efficiency.”
Siemens Healthineers (Erlangen, Germany), which is the separately managed healthcare business of Siemens AG (Munich, Germany) presented its latest Atellica Portfolio offerings at the Athens exhibition.
The Portfolio included: Atellica Solution (flexible, scalable, automation-ready immunoassay, and clinical chemistry analyzers), Atellica 1500 Automated Urinalysis System (fully digital, automated urinalysis system), Atellica NEPH 630 System (mid-volume, dedicated nephelometric system that simplifies specialty protein testing), Atellica COAG 360 System (fully automated high-volume coagulation system that unifies five testing methodologies), Atellica MDX 160 System (flexible, automated molecular system with maximum productivity for multiple sample types), and Atellica PM 1.0 Software (process management software to optimize lab operations through data analytics and visualization).
In addition, the Athens presentation featured the RAPIDComm Data Management System, which enables centrally managed point-of-care testing programs through a single customizable interface.
“The 2017 product display from Siemens Healthineers represents our focus on engineering success and pioneering healthcare,” said Franz Walt, president of laboratory diagnostics at Siemens Healthineers. “The Atellica portfolio epitomizes engineering excellence - with revolutionary innovations designed to give lab professionals control and simplicity so they can spend less time on operations and more time on driving better outcomes.”
“The informatics solutions from Siemens Healthineers are designed to address connectivity challenges to help position point-of-care testing programs for success,” said Peter Koerte, president of point-of-care diagnostics at Siemens Healthineers. “Through open connectivity to more than 150 devices from all leading point-of-care vendors, we deliver secure - yet flexible - connectivity options that increase both choice and performance for greater efficiency.”
Latest Technology News
- Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
- Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
- Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
- Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
- Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
- Smartphones Could Diagnose Diseases Using Infrared Scans
- Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
- 3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
- POC Paper-Based Sensor Platform to Transform Cardiac Diagnostics
- Study Explores Impact of POC Testing on Future of Diagnostics
- Low-Cost, Fast Response Sensor Enables Early and Accurate Detection of Lung Cancer
- Nanotechnology For Cervical Cancer Diagnosis Could Replace Invasive Pap Smears
- Lab-On-Chip Platform to Expedite Cancer Diagnoses
- Biosensing Platform Simultaneously Detects Vitamin C and SARS-CoV-2
- New Lens Method Analyzes Tears for Early Disease Detection
- FET-Based Sensors Pave Way for Portable Diagnostic Devices Capable of Detecting Multiple Diseases
Channels
Clinical Chemistry
view channel
AI-Powered Blood Test Accurately Detects Ovarian Cancer
Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more
Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
Current circulating cell-free DNA (cfDNA) assays are typically centralized, requiring specialized handling and transportation of samples. Introducing a flexible, decentralized sequencing system at the... Read moreMass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read moreMolecular Diagnostics
view channel
POC Diagnostic Platform Combines Immunoassay and Molecular Testing
An innovative diagnostic platform offers superior sensitivity across all sample types, including blood, compared to existing rapid tests, while maintaining a low-cost, user-friendly design.... Read more
Single Blood Test Could Detect Different Types of Cancer at Early Stages
Currently, reliable screening for only a few types of cancer is available, such as those affecting the breast, bowel, cervix (neck of the womb), and lung for individuals at high risk. While these screenings... Read moreHematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
New Blood Test Detects Up to Five Infectious Diseases at POC
Researchers have developed a prototype flow-through assay capable of detecting up to five different infections, with results that can be quickly analyzed and transmitted via a specialized smartphone app.... Read more
Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, led to 1.25 million deaths in 2023, with 13% of those occurring in people living with HIV. The current primary diagnostic method for... Read morePathology
view channel
Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. With EDs often being some of the busiest... Read more
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read moreIndustry
view channel
Qiagen Acquires NGS Analysis Software Company Genoox
QIAGEN (Venlo, the Netherlands) has signed a definitive agreement to acquire Genoox (Tel Aviv, Israel), a provider of artificial intelligence (AI)-powered software that enables clinical labs to scale and... Read more
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more